Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO Annual Meeting, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.

April 7, 2017

The Cancer Survivorship Symposium: Advancing Care and Research was held on January 27 and 28, in San Diego. Symposium content centered on collaboration between primary care physicians and oncologists.

Read more
April 7, 2017

Vamsidhar Velcheti, MD, and his team have been investigating why some people respond to immunotherapy while others do not.

Read more
April 7, 2017

The 2017 ASCO Quality Care Symposium featured wide-ranging discussions of advances in patient care, implementation science, unmet needs in oncology care, and more.

Read more
April 7, 2017

The inaugural ASCO Oncology Practice Conference, held in Orlando, Florida, on March 2, brought together experts in the business of cancer care to discuss challenges faced by oncology practices. 

Read more
April 7, 2017

The 2017 Clinical Immuno-Oncology Symposium achieved a successful first year, in which 950 physicians, researchers, translation-oriented scientists, and others gathered to learn about state-of-the-art developments in the science and application of immuno-oncology. 

Read more
April 7, 2017

The 2017 Genitourinary Cancers Symposium featured a wide variety of novel and important research across a variety of specific fields.

Read more
April 7, 2017

The 2017 Gastrointestinal Cancers Symposium concluded another year of enlightening discourse, multidisciplinary education, and fruitful interaction among the more than 3,500 attendees.

Read more
April 7, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more
April 7, 2017

A number of factors affecting oncologists’ work are leading to discontent with their career and pose a threat to their wellness.

Read more

April 7, 2017

Robert Dreicer, MD, MS, FACP, FASCO, answers a question posed by an attendee during a Best of ASCO Meeting.

Read more
June 6, 2016

Although the field is in its infancy with regard to clinical data, there is increasing interest in combining checkpoint inhibitor therapy with surgery and/or radiotherapy in head and neck cancers. 

Read more
June 6, 2016

Drug development in oncology is providing much-needed new therapies to patients living with cancer. 

Read more
June 6, 2016

A proprietary plasma DNA genomic sequencing platform demonstrated high sensitivity and positive predictive value and detected mutation sequences that confer resistance to therapy.

Read more
June 6, 2016

Results from the FAST study demonstrated that IMAB362, an antibody against claudin, a tight junction protein, significantly prolonged median PFS and OS in gastric cancers. 

Read more
June 7, 2016

The costs of cancer drugs can vary widely around the world and appear to rise unpredictably and irrespective of typical market forces from the time of their launch. 

Read more
June 7, 2016

Intensification of myeloablative therapy with tandem autologous stem cell transplant (ASCT) improved the probability of survival in patients with high-risk neuroblastoma, with no increase in toxicity, according to a Late Breaking Abstract (LBA3).

Read more
June 6, 2016

Pembrolizumab exhibited clinically significant antitumor activity against recurrent or metastatic head and neck squamous cell carcinoma in a phase II clinical trial. 

Read more
June 6, 2016

A cytarabine and daunorubicin liposomal drug delivery platform outperformed 7+3 drug delivery in a phase III trial for secondary AML. 

Read more
June 6, 2016

A large study found that the individual surgeon and the institution exert greater influence on whether patients undergo mastectomy versus lumpectomy compared with all other clinical and demographic variables, except for tumor size and nodal status.

Read more
June 6, 2016

A study demonstrated that SRS following surgery was noninferior to WBRT for treatment of 1-4 brain metastases, but had a more favorable safety profile, especially with respect to cognitive outcomes.

Read more